Evaluation of serine treatment for the prevention of osteoporosis in premenopausal and early postmenopausal women who are taking antidepressants medication

Prediction, early diagnosis and grading of osteoporosis based on MRI UTE-2 quantification and next-generation targeted metabolomic analysis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023505

Enrollment

Unknown

Registered

2019-05-31

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Group 1:Antidepressant+ Serine treatment (Two tablets, 1 g per day)

Group 2:Antidepressant + placebo, Take a placebo once a day for 9 months

Group 3:No antidepressant with placebo group

Eligibility

Sex/Gender

Female

Age

45 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Women aged between 45 and 55 years; (2) Perimenopause or menopause (change in regularity of menses in past 12 month, or no period in past 12 month); (3) Participant with a whole uterus and at least one ovary; (4) Using antidepressants such as fluoxetine and desipramine in the last 1 month, but less than 3 months and will continue to take antidepressants during the study.

Exclusion criteria

Exclusion criteria: With other major diseases include severe diabetes, coronary vascular disease and malignant tumors, renal failure; prior fracture or osteoporosis; used estrogen or other medications known to affect ovarian function.

Design outcomes

Primary

Measure	Time frame
Lumbar spine bone mineral density;	—

Secondary

Measure	Time frame
Depression scale score;Anxiety scale score;	—

Countries

China

Contacts

Public ContactShihong Li

Jiangsu Vocational College of Medicine

leekefeng@hotmail.com+86 13521253262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026